ProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation

ProMetic Life Sciences Inc.’s (TSX:PLI) plasminogen drug Ryplazimä has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration, renewing investor interest in the Canadian bio-pharmaceutical company.

The Motley Fool

Today, shares of ProMetic Life Sciences Inc.(TSX:PLI) jumped more than 21% in early morning trading on news that its plasminogen drug, Ryplazimä, has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration (FDA), a drug which I covered in late December amid the beginning of a slide which has continued for ProMetic since the beginning of the year.

My thesis at the time was that the pipeline of drugs for ProMetic was not being accurately priced by the market, with the probability of success for the company’s Ryplazimä not fully appreciated by the market at the time. Despite the company’s stock price dipping another 35% since my initial article on the bio-pharmaceutical company, this most recent rebound following news of the FDA designation has sent ProMetic’s share price abruptly higher, reflecting much of the positive market sentiment stemming from the new designation.

The FDA has now provided three designations for Ryplazimä; in addition to a Rare Pediatric Disease designation, the drug has also received Orphan Drug status as well as Fast Track status — designations which highlight the importance of the drug and the current unmet need in the market for plasminogen treatments such as Ryplazimä.

If Ryplazimä indeed receives final FDA approval, the drug is in line to receive a rare pediatric disease priority voucher, which can be used to accelerate the review of an existing drug within the company’s pipeline or be sold off to a third party for a tidy profit. This is a rare asset handed out only in cases of significant unmet need: a scenario which has played out in favour of ProMetic’s Ryplazimä drug.

ProMetic’s chief executive officer Pierre Laurin spoke to the recent FDA announcement in a press release:

“We are pleased that RyplazimäTM has received this pediatric designation from the FDA. In addition to Ryplazimä’sTM orphan drug status, this designation represents another validation of the approach we have taken regarding our plasminogen’s clinical program…The pediatric designation also provides an important incentive for ProMetic to continue developing therapies addressing unmet medical needs for children with rare diseases. We look forward to continue to work closely with the FDA to bringing this innovative therapy to patients suffering from plasminogen deficiency.”

Bottom line

This is yet another step in the right direction for ProMetic — a company with a significant amount of promise in the Canadian bio-pharmaceutical space, one which has been hit hard in recent years. I will be watching this company closely over the coming weeks and months as new developments continue to roll in.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Chris MacDonald has no position in any stocks mentioned in this article.

More on Investing

think thought consider
Tech Stocks

Is CGI Stock a Buy Even With No Dividend Yield?

CGI stock may not have a dividend to speak of. But does that necessarily mean you should ignore this top…

Read more »

A robotic hand interacting with a visual AI touchscreen display.
Tech Stocks

Why Now Is the Time to Invest in Canadian AI Stocks

Are you looking for one of the most solid Canadian AI stocks out there? This one is probably your best…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

Why AI Stocks Should Be in Every Canadian Investor’s Portfolio

AI stocks continue to be one of the best options out there for long-term investing, especially when considering Canadian options.

Read more »

stock research, analyze data
Bank Stocks

Canadian Bank Stocks: Buy, Sell, or Hold?

There are opportunities and risks on the horizon for the Canadian banks.

Read more »

Young Boy with Jet Pack Dreams of Flying
Stock Market

Is Air Canada Stock a Good Buy After Its Q3 Results

Down almost 60% from all-time highs, Air Canada is an undervalued TSX stock that remains an enticing investment in November…

Read more »

cloud computing
Investing

Where to Invest $10,000 in November

Given their solid underlying businesses and healthy growth prospects, I expect these two defensive stocks to outperform uncertain outlook.

Read more »

coins jump into piggy bank
Retirement

Here’s the Average RRSP Balance at Age 44 for Canadians

Holding stocks like Alimentation Couche-Tard (TSX:ATD) in an RRSP is a good way to build your wealth.

Read more »

dividends can compound over time
Dividend Stocks

Want a 7% Yield? The 3 TSX Stocks to Buy Today

These TSX stocks are offering high yields of over 7%, making them attractive for investors seeking steady passive income.

Read more »